Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200461162> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W4200461162 endingPage "23" @default.
- W4200461162 startingPage "16" @default.
- W4200461162 abstract "Telogen Effluvium (TE) in a post-Covid-19 patient causes excessive shedding of hair. No definite treatment is available till now. Past studies demonstrates that QR678Neo® has shown promising results in various types of Alopecia.In this study, we aim to establish efficacy of QR678 Neo® hair growth factor formulation administration in Covid-19-induced persistent TE for treatment of hair loss and for hair regrowth.Twenty adult patients (all females) presenting with persistent TE starting few weeks after recovery from Covid-19 infection, and continuing beyond 6 months were included for the study. A 1.5 mL solution of QR678 Neo® hair growth factor formulation was administered in the scalp per session. A total of 8 sessions (one session every 4 weeks) were done. The results were assessed at the baseline, after 4thsession, and 1 month after 8th session.Most of the patients showed significant reduction in hair fall; 89% patients showed excellent hair growth. Global photographic assessment score showed marked improvement, which maintained even post therapy. Videomicroscopic assessment showed increase in the hair count (mean =29.32) after 8th session, that further improved even post therapy. The subjective assessment scores for overall hair growth, appearance of hair, reduction in visibility of the scalp, and hair loss were 4, 4.5, 4.25, and 5, respectively.Management of Covid-19-induced persistent Telogen Effluvium has been unclear and futile so far. Intra-dermal administration of QR678 Neo® hair growth factor formulation in the scalp, reduces hair fall, improves hair regrowth, and increases the hair density." @default.
- W4200461162 created "2021-12-31" @default.
- W4200461162 creator A5009115592 @default.
- W4200461162 creator A5014000091 @default.
- W4200461162 creator A5041343427 @default.
- W4200461162 creator A5055294073 @default.
- W4200461162 creator A5067899803 @default.
- W4200461162 date "2021-12-07" @default.
- W4200461162 modified "2023-09-27" @default.
- W4200461162 title "Efficacy of QR678 Neo <sup>®</sup> hair growth factor formulation for the treatment of hair loss in Covid‐19‐induced persistent Telogen Effluvium—A prospective, clinical, single‐blind study" @default.
- W4200461162 cites W1543028606 @default.
- W4200461162 cites W1965589936 @default.
- W4200461162 cites W1978879499 @default.
- W4200461162 cites W1997754735 @default.
- W4200461162 cites W2082095193 @default.
- W4200461162 cites W2128568150 @default.
- W4200461162 cites W2615400083 @default.
- W4200461162 cites W2789814156 @default.
- W4200461162 cites W2950398511 @default.
- W4200461162 cites W2969862999 @default.
- W4200461162 cites W3018536678 @default.
- W4200461162 cites W3049563959 @default.
- W4200461162 cites W3107726527 @default.
- W4200461162 cites W3123123255 @default.
- W4200461162 cites W3129440064 @default.
- W4200461162 cites W3143401394 @default.
- W4200461162 cites W3216139118 @default.
- W4200461162 cites W4211185602 @default.
- W4200461162 doi "https://doi.org/10.1111/jocd.14626" @default.
- W4200461162 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34875139" @default.
- W4200461162 hasPublicationYear "2021" @default.
- W4200461162 type Work @default.
- W4200461162 citedByCount "4" @default.
- W4200461162 countsByYear W42004611622022 @default.
- W4200461162 countsByYear W42004611622023 @default.
- W4200461162 crossrefType "journal-article" @default.
- W4200461162 hasAuthorship W4200461162A5009115592 @default.
- W4200461162 hasAuthorship W4200461162A5014000091 @default.
- W4200461162 hasAuthorship W4200461162A5041343427 @default.
- W4200461162 hasAuthorship W4200461162A5055294073 @default.
- W4200461162 hasAuthorship W4200461162A5067899803 @default.
- W4200461162 hasConcept C126322002 @default.
- W4200461162 hasConcept C16005928 @default.
- W4200461162 hasConcept C2776360568 @default.
- W4200461162 hasConcept C2778515351 @default.
- W4200461162 hasConcept C2779134260 @default.
- W4200461162 hasConcept C3008058167 @default.
- W4200461162 hasConcept C3020618081 @default.
- W4200461162 hasConcept C42407357 @default.
- W4200461162 hasConcept C524204448 @default.
- W4200461162 hasConcept C71924100 @default.
- W4200461162 hasConceptScore W4200461162C126322002 @default.
- W4200461162 hasConceptScore W4200461162C16005928 @default.
- W4200461162 hasConceptScore W4200461162C2776360568 @default.
- W4200461162 hasConceptScore W4200461162C2778515351 @default.
- W4200461162 hasConceptScore W4200461162C2779134260 @default.
- W4200461162 hasConceptScore W4200461162C3008058167 @default.
- W4200461162 hasConceptScore W4200461162C3020618081 @default.
- W4200461162 hasConceptScore W4200461162C42407357 @default.
- W4200461162 hasConceptScore W4200461162C524204448 @default.
- W4200461162 hasConceptScore W4200461162C71924100 @default.
- W4200461162 hasIssue "1" @default.
- W4200461162 hasLocation W42004611621 @default.
- W4200461162 hasLocation W42004611622 @default.
- W4200461162 hasOpenAccess W4200461162 @default.
- W4200461162 hasPrimaryLocation W42004611621 @default.
- W4200461162 hasRelatedWork W16045063 @default.
- W4200461162 hasRelatedWork W2048992728 @default.
- W4200461162 hasRelatedWork W2109794961 @default.
- W4200461162 hasRelatedWork W2419672018 @default.
- W4200461162 hasRelatedWork W2996753999 @default.
- W4200461162 hasRelatedWork W4224078112 @default.
- W4200461162 hasRelatedWork W4235694801 @default.
- W4200461162 hasRelatedWork W4285984934 @default.
- W4200461162 hasRelatedWork W4295254635 @default.
- W4200461162 hasRelatedWork W2185654466 @default.
- W4200461162 hasVolume "21" @default.
- W4200461162 isParatext "false" @default.
- W4200461162 isRetracted "false" @default.
- W4200461162 workType "article" @default.